Skip to main content
Journal cover image

Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community.

Publication ,  Journal Article
Kunimura, A; Yano, Y; Hisamatsu, T; Torii, S; Kondo, K; Kadota, A; Fujiyoshi, A; Okamura, T; Watanabe, Y; Shiino, A; Nozaki, K; Ueshima, H ...
Published in: Eur J Neurol
May 2023

BACKGROUND AND PURPOSE: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new target for reducing low-density lipoprotein cholesterol and incident cardiovascular disease, including stroke. However, the clinical relevance of circulating PCSK9 levels has been poorly elucidated in the general population, particularly in association with subclinical cerebrovascular disease including cerebral small vessel disease (CSVD) and intracranial artery stenosis (ICAS). METHODS: In community-dwelling Japanese men (n = 526) aged 46-82 years without a history of cardiovascular disease, the associations of serum PCSK9 levels with the prevalence of CSVD and ICAS were assessed using magnetic resonance imaging. CSVD included lacunar infarction, deep and subcortical white matter hyperintensity, periventricular hyperintensity and cerebral microbleeds. RESULTS: The median (interquartile range) age at baseline and serum PCSK9 levels were 69 (63-74) years and 240 (205-291) ng/ml, respectively. After adjusting for traditional cardiovascular risk factors including low-density lipoprotein cholesterol, multivariable Poisson regression with robust error variance revealed a significant association between PCSK9 levels (per 1 SD) and ICAS (relative risks 1.18, 95% confidence interval 1.02-1.37). Multivariable ordinal logistic regression for ICAS, with stenosis graded as mild (<50%) or moderate-severe (≥50%), revealed a similar association (common odds ratio 1.31, 95% confidence interval 1.04-1.64). However, no significant association was observed between serum PCSK9 levels and CSVD. CONCLUSIONS: Higher circulating PCSK9 levels were independently associated with an ICAS prevalence but not with CSVD prevalence. The quantification of circulating PCSK9 levels may help to identify individuals at high risk for cerebrovascular disease in the general population.

Duke Scholars

Published In

Eur J Neurol

DOI

EISSN

1468-1331

Publication Date

May 2023

Volume

30

Issue

5

Start / End Page

1327 / 1334

Location

England

Related Subject Headings

  • Subtilisins
  • Stroke
  • Proprotein Convertase 9
  • Neurology & Neurosurgery
  • Middle Aged
  • Male
  • Humans
  • Constriction, Pathologic
  • Cholesterol, LDL
  • Cardiovascular Diseases
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kunimura, A., Yano, Y., Hisamatsu, T., Torii, S., Kondo, K., Kadota, A., … SESSA research group. (2023). Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community. Eur J Neurol, 30(5), 1327–1334. https://doi.org/10.1111/ene.15723
Kunimura, Ayako, Yuichiro Yano, Takashi Hisamatsu, Sayuki Torii, Keiko Kondo, Aya Kadota, Akira Fujiyoshi, et al. “Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community.Eur J Neurol 30, no. 5 (May 2023): 1327–34. https://doi.org/10.1111/ene.15723.
Kunimura A, Yano Y, Hisamatsu T, Torii S, Kondo K, Kadota A, et al. Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community. Eur J Neurol. 2023 May;30(5):1327–34.
Kunimura, Ayako, et al. “Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community.Eur J Neurol, vol. 30, no. 5, May 2023, pp. 1327–34. Pubmed, doi:10.1111/ene.15723.
Kunimura A, Yano Y, Hisamatsu T, Torii S, Kondo K, Kadota A, Fujiyoshi A, Okamura T, Watanabe Y, Shiino A, Nozaki K, Ueshima H, Miura K, SESSA research group. Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community. Eur J Neurol. 2023 May;30(5):1327–1334.
Journal cover image

Published In

Eur J Neurol

DOI

EISSN

1468-1331

Publication Date

May 2023

Volume

30

Issue

5

Start / End Page

1327 / 1334

Location

England

Related Subject Headings

  • Subtilisins
  • Stroke
  • Proprotein Convertase 9
  • Neurology & Neurosurgery
  • Middle Aged
  • Male
  • Humans
  • Constriction, Pathologic
  • Cholesterol, LDL
  • Cardiovascular Diseases